Search results for: France
Filter search results
Biosimilar Competition: Lessons from Europe and Prospects for the US
2 December 2014
…granulocyte-colony-stimulating-factors (G-CSFs) has evolved since 2009 in France, Germany, Italy, Sweden and the UK. The author highlights two key results. Firstly, the market experience varies greatly across product classes…
Recently Published: New Report Comparing Usage of Medicines in the UK with Other Countries
6 January 2015
…of medicines in the UK relative to 12 comparable high-income countries including France, Germany, Italy, Spain and the USA. Sixteen classes of medicines were included in the original Richards report…
Trade and Price Differentials for Pharmaceuticals: Policy Options
1 May 1997
…countries, such as France, Spain or Greece, into countries with higher prices, such as Germany, the UK or the Netherlands. The European Court of Justice has upheld parallel importing, as…
OHE at HTAi Oslo: A New Drug Development Paradigm, a Framework for Developing Formularies in MICs, and the Effect of NICE Decisions Abroad
15 June 2015
…Denmark, France, Italy, Korea, Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia, Ecuador, Egypt and Ghana). Information regarding NICE HTA recommendations was extracted from NICE’s website and HTAinSite.com, and additional information…
Biosimilars’ Price Dynamic in Europe
30 June 2010
…seminar and summarises the remarks of Dr Matthias Liefner of Simon Kucher and Partners. In Europe, pricing of biosimilars already has begun to affect the market for biologics. For example, France’s compulsory…
Chronic Venous Diseases of the Leg
1 December 1992
…estimates of their economic cost in five European countries, Britain, France, Germany, Italy and Spain. It reviews the benefits and risks of alternative treatments and highlights the potential for innovations…
Measuring the Benefits of Medicines: The Future Agenda
1 March 1990
…Europe. In his keynote speech. Sir Christopher France referred to health economics as having ‘come of age’ because the first health economist in the then Ministry of Health in London…
OHE at HTAi Oslo: A New Drug Development Paradigm, and the Effect of NICE Decisions Abroad
19 June 2015
…of 29 drug/indication pairs and a group of 15 countries were studied (Australia, Canada, Denmark, France, Italy, Korea, Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia, Ecuador, Egypt and Ghana). The…
Data Governance Arrangements for Real-World Evidence: South Korea
1 September 2017
…(RWE), thereby working toward a set of “international standards”1. The analysis was based on a study of governance arrangements in eight key markets: the UK, France, Italy, Sweden, Germany, the…